vorinostat has been researched along with Cancer, Second Primary in 4 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Glasser, CL | 1 |
| Lee, A | 1 |
| Eslin, D | 1 |
| Marks, L | 1 |
| Modak, S | 1 |
| Glade Bender, JL | 1 |
| Rich, A | 1 |
| Sun, J | 1 |
| Aldayel, AS | 1 |
| Yin, CC | 1 |
| Medeiros, LJ | 1 |
| Konoplev, S | 1 |
| Jones, JR | 1 |
| Cairns, DA | 1 |
| Gregory, WM | 1 |
| Collett, C | 1 |
| Pawlyn, C | 1 |
| Sigsworth, R | 1 |
| Striha, A | 1 |
| Henderson, R | 1 |
| Kaiser, MF | 1 |
| Jenner, M | 1 |
| Cook, G | 1 |
| Russell, NH | 1 |
| Williams, C | 1 |
| Pratt, G | 1 |
| Kishore, B | 1 |
| Lindsay, J | 1 |
| Drayson, MT | 1 |
| Davies, FE | 1 |
| Boyd, KD | 1 |
| Owen, RG | 1 |
| Jackson, GH | 1 |
| Morgan, GJ | 1 |
| Smeltzer, JP | 1 |
| Viswanatha, DS | 1 |
| Habermann, TM | 1 |
| Patnaik, MM | 1 |
1 review available for vorinostat and Cancer, Second Primary
| Article | Year |
|---|---|
Myelomastocytic leukemia with aberrant CD25 expression: case report and review of the literature.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2014 |
1 trial available for vorinostat and Cancer, Second Primary
| Article | Year |
|---|---|
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease- | 2016 |
2 other studies available for vorinostat and Cancer, Second Primary
| Article | Year |
|---|---|
Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.
Topics: Adolescent; Antineoplastic Agents; Azacitidine; Decitabine; Drug Therapy, Combination; Epigenesis, G | 2017 |
Secondary Epstein-Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic T cell lymphoma on vorinostat.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Epstein-Barr Virus Infections; Female; Humans; Hydro | 2012 |